<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03587194</url>
  </required_header>
  <id_info>
    <org_study_id>AP-CL-PSOR-PI-13156</org_study_id>
    <nct_id>NCT03587194</nct_id>
  </id_info>
  <brief_title>Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis</brief_title>
  <official_title>A Single Center Study to Evaluate the Effectiveness and Safety of Add on Enstilar® in Patients Using OTEZLA® for Moderate to Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Psoriasis Treatment Center of Central New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Psoriasis Treatment Center of Central New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with moderate to severe plaque psoriasis will be treated with Otezla BID. At week 8,
      non responders will be discontinued, partial responders will be given add-on Enstilar QD for
      4 weeks and PASI 75 responders will remain on Otezla monotherapy through week 16.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      50 adult patients with moderate to severe plaque psoriasis will be given OTEZLA® for 8 weeks.

      At week 8, patients who achieved between PASI 25-74 response will receive 4 weeks of
      Enstilar® (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064% in addition to
      continuing OTEZLA® therapy.

      Patients who do not meet PASI 25 at week 8 will be discontinued from the study.

      At week 12 (after 4 consecutive weeks of Enstilar® add on therapy), Enstilar® will be
      discontinued and these patients will continue Otezla® as monotherapy through week 16.

      Patients who achieve PASI 75 at week 8 will remain enrolled on Otezla® monotherapy through
      week 16.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psoriasis Area Severity Index 75 at week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patients who achieve Psoriasis Area Severity Index 75 at week 12. PASI scores range 0-72 (maximal disease)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Otezla</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Otezla BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Otezla</intervention_name>
    <description>Otezla 30mg BID</description>
    <arm_group_label>Otezla</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female adult ≥ 18 years of age;

          2. Diagnosis of chronic plaque-type psoriasis

          3. Moderate to severe plaque type psoriasis as defined at baseline by:

               -  PGA score of 3 or greater

               -  BSA affected by plaque-type psoriasis of 10% or greater

               -  PASI ≥ 12

          4. Able and willing to give written informed consent prior to performance of any
             study-related procedures

          5. Must be in general good health (except for disease under study) as judged by the
             Investigator, based on medical history, physical examination, clinical laboratories,
             and urinalysis. (NOTE: The definition of good health means a subject does not have
             uncontrolled significant co-morbid conditions).

        Exclusion Criteria:

          1. Other than psoriasis, any clinically significant (as determined by the investigator)
             cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal,
             hematologic, immunologic disease, or other major disease that is uncontrolled.

          2. Forms of psoriasis other than chronic plaque-type (e.g., Pustular erythrodermic and/or
             guttate psoriasis) or drug induced psoriasis

          3. Subjects who previously used any biologic agent for psoriasis.

          4. Use of oral systemic medications for the treatment of psoriasis within 4 weeks
             (includes, but not limited to, oral corticosteroids, methotrexate, acitretin and
             cyclosporine).

          5. Patient used topical therapies to treat psoriasis on the hands and/or feet within 2
             weeks of the Baseline Visit (includes, but not limited to, topical corticosteroids,
             vitamin D analogs, or retinoids).

          6. Patient received UVB phototherapy within 2 weeks of Baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jerry Bagel, MD</last_name>
    <phone>6094434500</phone>
    <email>dreamacres1@aol.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elise Nelson</last_name>
    <phone>6094434500</phone>
    <email>enelson@windsordermatology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Psoriasis Treatment Center of Central New Jersey</name>
      <address>
        <city>East Windsor</city>
        <state>New Jersey</state>
        <zip>08520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jalyssa Delvalle</last_name>
      <phone>609-443-4500</phone>
      <phone_ext>1416</phone_ext>
      <email>jdelvalle@windsordermatology.com</email>
    </contact>
    <contact_backup>
      <last_name>Elise Nelson</last_name>
      <phone>6094434500</phone>
      <email>enelson@windsordermatology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jerry Bagel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Keegan, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Nieves, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2018</study_first_posted>
  <last_update_submitted>August 27, 2018</last_update_submitted>
  <last_update_submitted_qc>August 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apremilast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

